

SIMRIS ALG

INTERIM REPORT

JANUARY–JUNE 2022

THE PERIOD IN BRIEF - GROUP

SEK thousands	Apr-Jun 2022	Apr-Jun 2021	Δ	Jan-Jun 2022	Jan-Jun 2021	Δ	Full Year 2021
Net revenue	240	697	-66%	3 446	1 189	190%	6 137
EBITDA	-4 050	-6 095	34%	-7 470	-12 791	42%	-23 125
EBIT / Operating result	-4 767	-6 858	30%	-8 911	-14 320	38%	-28 928
Result before tax	-5 106	-7 188	29%	-9 113	-14 041	35%	-28 343
Cash flow from operating activities	-2 310	-4 633	50%	-5 601	-12 111	54%	-18 137
Cash at the end of the period	18 391	3 765	388%	18 391	3 765	388%	961

Note: numbers in brackets are comparable figures from the previous year.

Q2, APRIL-JUNE 2022

- Net revenue decreased by 66% to SEK 240k (697k).
- Personnel & other external costs decreased by 34% to SEK -4 257k (-6 424k)
- EBITDA improved by 34% to SEK -4 050k (-6 095k).
- EBIT/ Operating result improved by 30% to SEK -4 767k (-6 858k).

JANUARY -JUNE 2022

- Net revenue increased by 190% to SEK 3 446k (1 189k).
- Personnel & other external costs decreased by 38% to SEK -7 774k (-12 555k).
- EBITDA improved by 42% to SEK -7 470k (-12 791k).
- EBIT/ Operating result improved by 38% to SEK -8 911k (-14 320k).

KEY EVENTS IN Q2

- An Extraordinary General Meeting ("EGM") was held at Simris Alg Headquarters in Hammenhög, on April 8, 2022. Resolutions were passed relating to: (1) A Rights Issue of shares; (2) A directed issue of shares with payment by set-off, and (3) A directed issue of warrants, to which the incoming CEO, Julian Read, holds the right to subscribe.
- Simris Alg published an Investment Memorandum relating to a Rights Issue on 20 April 2022.
- Julian Read was appointed CEO of Simris Alg on May 16 2022.

- Simris Alg successfully completed a Rights Issue of shares for a total of SEK 25.1m as well as a directed issue of shares set-off against debt of SEK 6.2m.
- The issue of warrants to CEO Julian Read have been fully subscribed for, providing him with the right to subscribe for up to 3 500 000 new B shares.
- In a move to further internationalise the Company, the Board resolved to change the primary language of communication to English.
- The current Board was re-elected at the Annual General Meeting ("AGM") held at Simris Alg in Hammenhög, on 25 May 2022.

KEY EVENTS AFTER Q2

- Simris Alg announced a change of Certified Adviser to Amudova AB and the termination of its Liquidity Guarantee Service on 19th July 2022.
- Simris Alg AB released a CEO letter on Thursday 4th August, outlining the strategic direction to which the Board & management are committed, wherein Simris will enter high profit sectors through a mixture of internal investments in infrastructure & capability, targeted profitable acquisitions, and the re-launch a range of reformulated Simris branded supplements that will be regulatory compliant in all major markets.
- On 17th August 2022, Simris announced the earlier signing of a binding Letter of Intent to acquire all of the shares in Berlin-based Cyano Biotech GmbH.

ABOUT SIMRIS ALG AB (PUBL):

Simris Alg is a biotechnology company identifying high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in skincare, nutrition, and biopharmaceuticals. The company sustainably grows microalgae and cyanobacteria at industrial scale within its photobioreactor facility whereby conditions are optimized for production of these high-value compounds. Simris Alg's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664. Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.



WORDS FROM THE CEO

Upon joining Simris in the middle of the second quarter, I was grateful to the Board & Christoffer Tell (CFO) that they had made much progress on the re-structuring of operations. Reducing personnel & external costs by almost 40%, whilst increasing sales by 190% in H1 vs 2021, provided me with a good platform from which to start my work. I have therefore been able to focus on confirming the strategy and laying the foundations of the future Simris.



Julian Read
CEO

The long-term vision brought into Simris with the appointment of the new Board in May 2021, and that I wholeheartedly embrace, is that the Simris of today is a platform upon which we will build an enterprise operating across several high margin verticals, each selling a refined product. The team is now fully focused on realising this vision and it is through that lens that all decisions have been taken since I joined.

As communicated in my recent CEO letter, we plan to realise our vision through focused internal investments supplemented with targeted, accretive acquisitions. Any acquisition that we make will need to meet several of the following criteria: (1) Adds new competencies and capabilities; (2) Provides an accelerated entrance into a new vertical/product category; (3) Gives greater access to new geographies/ markets; (4) Has protected novel science/ technology; (5) Increases production capacity; and (6) Is profitable and thereby accretive to the value of the Simris share.

I was happy to be able to recently announce the signing of a Letter Of Intent ("LOI") with Cyano Biotech GmbH. This potential acquisition would provide us with an in-house R&D facility, a strong and well protected technology platform, deeper scientific competence, plus an entrance into the BioPharma space - in particular the field of ADCs* and cancer treatment.

Simris has invested significant time during Q2 to better its understanding of Cyano Biotech's potential and to negotiate favorable terms. These sessions have been highly constructive and set the path for us to unlock the full value of the identified synergies – which is what led us to the negotiation table in the first place. As I write this, we are deep into the confirmatory Due Diligence process and the deal is targeted to complete by the end of August.

GMP CERTIFICATION:

To unlock the full potential of Simris, whether it is selling novel cosmetic ingredients, best-in-class dietary supplements or anti-cancer toxins, we need to be able to guarantee our customers a consistently high-quality product. For this reason, we took the difficult decision to immediately prioritise the upgrading of our production facility over producing further fresh biomass this summer. During Q2, we began to invest in a structured

program designed to: (1) Improve biosecurity, (2) Give greater control over the growth conditions within each photobioreactor, and (3) Renew key system components. We also began new trials designed to test the effect of LED lighting on growth rates and yields. The full program of work is planned to continue into the early part of 2023 and is an essential first step in Simris' journey to gain the Good Manufacturing Process ("GMP") certification required to operate in high-margin industries such as BioPharma.

SHORT TERM REVENUE (H2 2022):

B2B: Net revenue for the first half of 2022 was 2.9x higher than in 2021. As reported in our Q1 report, two orders of fucoxanthin were invoiced in Q1. The second of these orders was actually pulled forward by the Buyer from the start of Q2. At this point they were expecting additional demand in Q2. The nature of a B2B model (especially in its early stages when there are relatively few customers), is that the phasing of orders is not smooth and can vary considerably from month to month. Whilst it is frustrating to report that there were no B2B sales in Q2, I am not overly concerned at this point in time. The interest shown by new potential customers, from as far afield as Japan, means that I remain confident in this becoming a sizeable revenue stream over the next 18 months.

B2C: All sales revenues generated in Q2 were from the sale of Simris branded supplements. The previous team built a strong supplement brand, based around sustainability, and protecting the natural environment. These themes resonate strongly with consumers and there is clearly considerable interest in vegan nutrients sourced from microalgae. However, the products were not approved for sale in the E.U., which was a severe constraint on growth. For this reason, we have reformulated the product to ensure full regulatory compliance in all major markets and we will re-launch these Simris branded supplements, in Q4. We are being careful to retain the core values of the brand whilst making the changes necessary to unlock a significantly higher sales volume. These changes include, smaller easy to swallow capsules, a higher concentration of active ingredients that unlock even greater health benefits, eCommerce friendly packaging, and a more competitive price.



* ADC = Antibody Drug Conjugate

** 2017 Slice Intelligence survey of U.S. shoppers

Sales in the United States will be direct to consumers through the Amazon platform. Amazon accounts for 77% of all vitamins & supplements sold online in the United States**. Our strategy is to initially focus on this channel at the re-launch with a marketing investment designed to ensure first page ranking. Our aim is to be amongst the top algae supplement brands on Amazon by the end of 2023. I am also delighted to be able to report that we will also be able to sell our reformulated products in Europe for the first time. The European launch is planned for Q1, 2023.

MID-TERM REVEUNE (2023):

B2B: Results from our R&D programme indicate that we can extract multiple compounds from the *Phaeodactylum tricornutum* biomass we produce. Through further extraction trials with contractors during Q3 and Q4 we will work to identify the conditions needed for optimum yields of each compound. This will position us to accelerate B2B sales in 2023 when we also aim to broaden our distribution into high value Asian markets.

B2C: I envision Simris expanding its range of dietary supplements by creating new products based upon novel ingredients, sourced

sustainably from both microalgae and cyanobacteria, and which already have broad regulatory approval in Europe, Australasia, and the United States.

LONG-TERM REVENUE (beyond 2023):

B2B: My expectation is that by 2024, Simris will have achieved GMP certification and will be operating within the BioPharma space. By partnering with pharmaceutical companies, I anticipate revenue generation from contract research, milestone payments, and eventually royalty payments, all from novel drug discovery projects. BioPharma is high risk, but also high reward. For example, a single ADC toxin making it into clinical use by a pharma partner, and produced for them from our photobioreactors, could be expected to sell for in the price range of €1m-€3m per kilogram in today's market. We believe that Simris' capability is and will be, a sustainable competitive advantage over other growers of microalgae and cyanobacteria.



Simris

OVERVIEW

NET REVENUE AND PROFIT

Net revenue during the second quarter amounted to SEK 240k (697k) and for the first half of the year amounted to SEK 3 446k (1 189k). The strong revenue increase in the first half of the year includes sales of B2B biomass where phasing and size of orders can be expected to fluctuate between quarters.

The operating result for the second quarter amounted to SEK -4 767k (-6 858k) and for the first half year to SEK -8 911k (-14 320k). The change in inventory during the second quarter amounted to SEK -56k (-58k) and the total inventory value by the end of the period amounted to SEK 858k (8 809k) at the end of the period. Raw materials, work in progress and finished product are all included in the inventory value.

FIXED ASSETS

The total value of the Group's fixed assets amounted to SEK 21 971k (27 694k) at the end of the period. Depreciation of fixed assets were made according to relevant accounting standards, with SEK 717k (763k) during the second quarter and with SEK 1 441k (1 529k) during the first half year. Fixed assets are depreciated over 5-10 years for most fixtures and fittings, and up to 40 years for the buildings.

LIQUIDITY AND FINANCING

Cash flow from operating activities amounted to SEK -2 310k (-4 633k) during the second quarter and SEK -5 601k (-12 111k) during the first half year. Cash flow amounted to SEK 17 449k (-4 698k) for the second quarter and SEK 17 430k (-12 747k) during the first half year. At the end of the period, cash and cash equivalents amounted to SEK 18 391k (3 765k). The total liabilities at the end of the period amounted to SEK 6 491k (8 859k).

During the third quarter of 2021, Simris Alg secured a bridge financing facility of up to SEK 7.0m in the form of a loan from Board Directors, shareholders, and external financiers. The loans were raised on commercial market terms and were drawn down by Simris based upon the company's liquidity needs. An amount of SEK 3 500k was drawn down during the first quarter. A resolution was passed at the EGM on April 8 approving a private placement of 19 276 182 B shares to the company's bridge loan issuer(s), with payment by set-off i.e., a conversion of debt to equity. To strengthen the company's Balance Sheet the lenders were given the opportunity to subscribe for shares, in lieu of cash repayment, at conclusion of the bridge loan term. Six out of seven bridge lenders elected to receive shares as repayment, and one elected to receive cash.

At the same, it was resolved to conduct a Rights Issue of approximately SEK 25.1m, with a subscription period beginning 21 April and ending 5 May 2022. The Rights Issue was subscribed to 110.1 percent. Through the subsequent issuance of 78 547 046 B shares, approximately SEK 25.1m was raised, before issuance costs. The Board's assessment is that the funds received from the Rights Issue will cover the company's capital needs beyond the end of the financial year 2022.

EQUITY

The Group's equity amounted to SEK 36 080k (33 206k) at the end of the period. The solidity was 84.8 percent, compared with 62.4 percent on December 31, 2021.

During the quarter the company has carried out two share issues; one rights issue and one directed share issue with right to set-off. The Rights Issue will increase the share capital of Simris Alg by SEK 6 821k through the issue of 78 547 046 B shares. The directed share issue of 19 276 182 shares of series B, was conducted at a price of SEK 0.32, as placed with the bridge loan lenders where payment was made through a right of set-off against debt. This has increased the share capital by SEK 1 675k. The total share capital after the two issues in the quarter amounted to SEK 15 322k.

SHARES AND THE OWNERS

The number of shares and votes in Simris Alg AB has changed as a result of the Rights Issue and offset issue during the quarter. The total number of shares on issue amounts to 176 370 274 B shares after the two issues.

As of June 30, 2022, Simris Alg AB had 6 671 shareholders (6 917), of which the ten largest had 30 percent of the share capital and the votes. Simris Alg's B shares have been listed on Nasdaq First North Growth Market since April 22, 2016. During the last quarter, the highest price paid for the share was SEK 0.850 and the lowest was SEK 0.238. The last paid price at the end of the period was SEK 0.338 which gave a market capitalization value of approximately SEK 60m. A total of 24.5 million shares were traded during the quarter.

OPTION PROGRAM

At the end of the period, Simris Alg had five outstanding Option programs.

Series 2019/1 consists of 43 438 options and was issued to employees of the company in May 2019. The options have a term of five years and for each option, 1.45 B shares can be subscribed for at a price of 4.44 SEK per share. Exercise of outstanding options corresponds to a dilution of the share capital by less than 0.1 percent.

Series 2021/2024:S consists of 2 000 000 options and was issued to the Board in May 2021. The options have a term of three years, and each option gives the right to subscription of 1.34 B shares at a subscription price of SEK 1.42 per share. Utilization of outstanding options correspond to a dilution of the share capital by 1.5 percent.

Series 2021/2024:L consists of 1 820 000 options and was issued to senior executives and employees in the company in May 2021. The options have a term of three years, and each option gives the right to subscription of 1.34 B shares at a subscription price of SEK 1.42 per share. Utilization of outstanding options correspond to a dilution of the share capital by 1.4 percent.

Series 2022/1 consists of 1 750 000 options and was issued to the CEO of the company in May 2022. The options have a term of three years, and each option gives the right to subscription of 1.34 B shares at a subscription price of SEK 0.91 per share. Utilization of outstanding options correspond to a dilution of the share capital by 1.3 percent.



Series 2022/2 consists of 1 750 000 options and was issued to the CEO of the company in May 2022. The options have a term of two years, and each option gives the right to subscription of 1.34 B shares at a subscription price of SEK 1.42 per share. Utilization of outstanding options correspond to a dilution of the share capital by 1.3 percent.

STAFF AND ORGANIZATION

During the quarter, two new employments were made. The average number employees amounted to 8 (15) during the quarter and 7 (17) in the period Jan to Jun.

PARENT COMPANY

As the Group consists of the parent company's assets, liabilities, and results to such a significant extent, no separate comments are made. Comments on the parent company are referred to in the comments on Group's earnings and position.

TRANSACTIONS WITH RELATED PARTIES

Chairman of the Board Steven Schapera and the Board Directors Robert Quandt and Frank Puccio have participated in the company's bridging loan facility with SEK 1.0m each. The bridging loans comprised a total of SEK 7.0m as of 31 March. The loans had a set-up fee of 5%, with an interest rate of 1% per month. The Loan plus interest were repaid during the quarter in a set-off issue at SEK 0.32 per share, i.e., the same price as the Rights Issue, as resolved at the EGM on April 8.

Chairman of the Board Steven Schapera and the Board Directors Robert Quandt and Frank Puccio also provided a guarantee, partially underwriting the company's Rights Issue during the second quarter with SEK 1.0m each. On identical terms to the other guarantor underwriters, they received 10% in commission for the guarantee, SEK 100k each.

In addition to normal Board work during the second quarter, Board Directors performed consulting services for the company, of which Brand Laboratories FZ LLC (a company associated with Steven Schapera), invoiced SEK 354k (including travel re-charges), Robert Quandt SEK 17k and Frank Puccio SEK 19k.

ANNUAL GENERAL MEETING

The AGM was held on May 25 2022, at which shareholders resolved to re-elect Steven Schapera, Magnus Högström, Frank Puccio and Robert Quandt to the board. The AGM further resolved that, on one or more occasion during the period, and until the next AGM, the Board are authorised to take decisions to increase the company's share capital through a new issue of series B shares and/or convertible notes and/or options entitled to convert to shares of series B.

ACCOUNTING PRINCIPLES

Simris Alg prepares its accounts in accordance with the Annual Accounts Act and the Accounting Boards general advice 2012:1(K3). Information on accounting principles in general is provided in the Financial Statement for 2021.

AUDIT

This report has not been reviewed by Simris Alg's auditor.

RISKS AND UNCERTAINTIES

Simris Alg's operations, financial position and earnings can be affected by a number of risks and uncertainties. These are described in Simris Alg's Financial Statement for 2021, at www.simrisalg.se/investerare.

Simris Alg assesses that the current Covid situation does not constitute a risk to the business.

Increased energy prices are an indirect impact resulting from the current situation in Ukraine. Other than additional cost, there is no direct impact on Simris Alg's operations.

The Board of Directors and the CEO assure that the interim report provides a fair overview of the group's operations, position and results.

Steven Schapera
Chairman

Magnus Högström
Board Director

Julian Read
CEO

Robert Quandt
Board Director

Frank Puccio
Board Director



INCOME STATEMENT - GROUP

SEK thousands	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Full year 2021
Net revenue	240	697	3 446	1 189	6 137
Change of finished goods and work in progress	-132	-52	-2 658	-114	-5 136
Activated work for own account	0	117	0	230	230
Other operating income	126	5	132	14	392
Raw materials and consumables	-27	-438	-616	-1 555	-3 298
Other external expenses	-2 583	-3 771	-4 681	-7 161	-12 316
Personnel expenses	-1 674	-2 653	-3 093	-5 394	-9 134
Depreciation and amortization	-717	-763	-1 441	-1 529	-5 803
Operating result / EBIT	-4 767	-6 858	-8 911	-14 320	-28 928
Financial net	-339	-330	-202	279	585
Result before tax	-5 106	-7 188	-9 113	-14 041	-28 343
Tax	-5	-35	-30	-11	-13
Result for the period	-5 111	-7 223	-9 143	-14 052	-28 356
(Attributable to the parent company's shareholders)	-5 111	-7 223	-9 143	-14 052	-28 356

BALANCE SHEET - GROUP

SEK thousands	30 Jun 2022	30 Jun 2021	31 Dec 2021
Assets			
Fixed Assets			
Intangible assets	0	2 693	0
Tangible assets	21 915	24 936	23 356
Financial assets	56	65	70
Total Fixed Assets	21 971	27 694	23 426
Current Assets			
Inventory	858	8 809	3 348
Other receivables	1 351	1 797	1 466
Cash and bank balances	18 391	3 765	961
Total Current Assets	20 600	14 371	5 775
Total Assets	42 571	42 065	29 201
Equity and Liabilities			
Equity	36 080	33 206	18 221
Provisions			
Deferred tax	94	80	87
Liabilities			
Long-term Liabilities	1 456	2 061	1 808
Short-term Liabilities	4 941	6 718	9 085
Total Liabilities	6 491	8 859	10 980
Total Equity and Liabilities	42 571	42 065	29 201



CASH FLOW ANALYSIS - GROUP

SEK thousands	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Full year 2021
Cash flow from operating activities before changes in working capital	-3 992	-6 189	-7 562	-12 889	-23 599
Cash flow from working capital	1 682	1 556	1 961	778	5 462
Cash flow from operating activities	-2 310	-4 633	-5 601	-12 111	-18 137
Cash flow from investing activities	0	9	0	-253	-253
Cash flow from financing activities	19 759	-74	23 031	-383	2 839
Cash flow for the period	17 449	-4 698	17 430	-12 747	-15 551
Cash and cash equivalents opening balance	942	8 463	961	16 512	16 512
Cash and cash equivalents closing balance	18 391	3 765	18 391	3 765	961

CHANGE IN EQUITY - GROUP

SEK thousands	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Full year 2021
Opening balance	13 902	40 006	18 221	47 423	47 423
Issue (including issue costs)	26 778	-11	26 778	10	10
Stock option program	105	191	105	191	191
Translation differences	406	243	119	-366	-1 047
Result for the period	-5 111	-7 223	-9 143	-14 052	-28 356
Closing balance	36 080	33 206	36 080	33 206	18 221

KEY FIGURES - GROUP

SEK thousands	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Full year 2021
Net revenue (kSEK)	240	697	3 446	1 189	6 137
EBIT (kSEK)	-4 767	-6 858	-8 911	-14 320	-28 928
Cash at the end of the period (kSEK)	18 391	3 765	18 391	3 765	961
Equity (kSEK)	36 080	33 206	36 080	33 206	18 221
Earnings per share (SEK)	neg.	neg.	neg.	neg.	neg.
Earnings per share after full dilution (SEK)	neg.	neg.	neg.	neg.	neg.
Equity per share (SEK)	0,20	0,42	0,20	0,42	0,23
Equity per share after full dilution (SEK)	0,20	0,42	0,20	0,42	0,23
Number of shares, average	131 840 721	78 540 690	105 341 103	78 540 690	78 543 868
Number of shares, end of period	176 370 274	78 540 690	176 370 274	78 540 690	78 547 046
Number of shares after full dilution*	176 370 274	78 547 046	176 370 274	78 547 046	78 547 046
Solidity (%)	84,8	78,9	84,8	78,9	62,4
Balance sheet total (kSEK)	42 571	42 065	42 571	42 065	29 201
Cash liquidity (%)	400	83	400	83	27
Average number of employees	8	15	7	17	12

*SimrisAlg has five outstanding warrant programs. Dilution effects have not been taken into account for any of the programs for any of the above periods, as the average price of SimrisAlg's share in each period has been less than the subscription price in the programs. If full subscription takes place within the framework of the option programs, the number of shares will increase by 9 871 785.

KEY FIGURE DEFINITIONS

Balance sheet total – The sum of all assets in the balance sheet or sum of all liabilities and equity.

Equity per share – Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number of shares at the end of the period.

Equity per share after full dilution – Adjusted equity (equity and untaxed reserves less deferred tax) divided by the number shares at the end of the period taking into account after conversion and adjusted for effect of share-based payments.

Cash liquidity – Current assets excluding inventories and work in

progress as a percentage of current liabilities

Net revenue – Operating main income, invoiced costs, side income and income corrections.

Earnings per share – Earnings for the period divided by the number of shares after the end of the period.

Earnings per share after full dilution – Earnings for the period divided by number shares after the end of the period, taking into account after conversion and adjusted for effect of share-based payments.

Operating result – Result before financial expenses and tax.

Solidity – Adjusted equity at the end of the period as a percentage of total asset.



INCOME STATEMENT – PARENT COMPANY

SEK thousands	Apr-Jun 2022	Apr-Jun 2021	Jan-Jun 2022	Jan-Jun 2021	Full year 2021
Net revenue	61	935	2 992	1 568	5 887
Change of finished goods and work in progress	7	-226	-2 200	27	-4 531
Activated work for own account	0	117	0	230	230
Other operating income	126	6	132	15	392
Raw materials and consumables	-26	-438	-616	-1 555	-3 298
Other external expenses	-2 511	-3 101	-4 500	-5 764	-10 504
Personnel expenses	-1 674	-2 653	-3 093	-5 394	-9 134
Depreciation and amortization	-716	-760	-1 434	-1 522	-5 788
Operating result / EBIT	-4 733	-6 120	-8 719	-12 395	-26 746
Financial net	-20	-188	-205	542	-12 308
Result before tax	-4 753	-6 308	-8 924	-11 853	-39 054
Tax	-4	-4	-7	-4	-10
Result for the period	-4 757	-6 312	-8 931	-11 857	-39 064

BALANCE SHEET – PARENT COMPANY

SEK thousands	30 Jun 2022	30 Jun 2021	31 Dec 2021
Assets			
Fixed Assets			
Intangible assets	0	2 693	0
Tangible assets	21 915	24 923	23 350
Financial assets	9	9	9
Total Fixed Assets	21 924	27 625	23 359
Current Assets			
Inventory	637	8 073	2 840
Receivables from group companies	0	12 370	0
Other receivables	1 258	1 739	1 368
Cash and bank balances	17 957	3 492	753
Total Current Assets	19 852	25 674	4 961
Total Assets	41 776	53 299	28 320
Equity and Liabilities			
Equity	35 375	44 630	17 423
Provisions			
Deferred tax	94	80	87
Liabilities			
Long-term Liabilities	1 456	2 061	1 808
Short-term Liabilities	4 851	6 528	9 002
Total Liabilities	6 401	8 669	10 897
Total Equity and Liabilities	41 776	53 299	28 320





FINANCIAL CALENDAR:

Interim Report January–September 2022: 9 November 2022
Year-end Report 2022: 15 February 2023

FOR MORE INFORMATION:

Julian Read, CEO
Phone: +46 (0)767 888 212
Email: julian@simris.com

This information is information that Simris Alg is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 17 August 2022, 08.00 CET.